Real-world evidence - What is it and what can it tell us?

New England Journal of Medicine

Volumn 375, Issue 23, 2016, Pages 2293-2297

  Sherman, Rachel E ^a   Anderson, Steven A ^a   Dal Pan, Gerald J ^a   Gray, Gerry W ^a   Gross, Thomas ^b   Hunter, Nina L ^a   LaVange, Lisa ^a   Marinac Dabic, Danica ^b   Marks, Peter W ^a   Robb, Melissa A ^a   Shuren, Jeffrey ^b   Temple, Robert ^a   Woodcock, Janet ^a   Yue, Lilly Q ^a   Califf, Robert M ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b CENTER FOR DEVICES AND RADIOLOGICAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL STUDY; ELECTRONIC HEALTH RECORD; EVIDENCE BASED MEDICINE; HEALTH CARE DELIVERY; HEALTH CARE ORGANIZATION; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; PATIENT CARE; POINT OF CARE TESTING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REAL WORLD EVIDENCE; CLINICAL TRIAL (TOPIC); EVIDENCE BASED PRACTICE; FEE; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; LEGISLATION AND JURISPRUDENCE; METHODOLOGY; OBSERVATIONAL STUDY; PROCEDURES; UNITED STATES;

CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED PRACTICE; GOVERNMENT REGULATION; HUMANS; OBSERVATIONAL STUDIES AS TOPIC; PRESCRIPTION FEES; RESEARCH DESIGN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85002412626     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMsb1609216     Document Type: Article

References (35)

1. Network for Excellence in Health Innovation. Real world evidence: a new era for health care innovation. September 2015 (http://www.nehi.net/writable/publication-files/file/rwe-issue- brief-final.pdf).
2. Food and Drug Administration. Use of real-world evidence to support regulatory decision-making for medical devices: draft guidance for industry and Food and Drug Administration staff. July 27, 2016 (http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM513027.pdf).
3. Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer 2014; 110: 551-5.
4. Cziraky M, Pollock M. Real-world evidence studies. Applied Clinical Trials. October 12, 2015 (http://www.appliedclinicaltrial sonline.com/real-world-evidence-studies?pageID=1).
5. Cattell J, Chilukuri S, Levy M. How big data can revolutionize pharmaceutical R&D. McKinsey & Company, April 2013 (http://www.mckinsey.com/insights/health-systems-and-services/how-big-data-can-revolutionize-pharmaceutical-r-and-d).
6. Kramer JM, Schulman KA. Appendix F - discussion paper: transforming the economics of clinical trials. In: Institute of Medicine. Envisioning a transformed clinical trials enterprise in the United States: establishing an agenda for 2020: workshop summary. Washington, DC: National Academies Press, 2012 (http://www.ncbi.nlm.nih.gov/books/NBK114653/).
7. Berndt ER, Cockburn IM. Price indexes for clinical trial research: a feasibility study. Bureau of Labor Statistics Monthly Labor Review. June 2014 (http://www.bls.gov/opub/mlr/2014/article/price-indexes-for-clinical-trial-research-a-feasibility-study-1.htm).
8. Zeevi D, Korem T, Zmora N, et al. Personalized nutrition by prediction of glycemic responses. Cell 2015; 163: 1079-94.
9. Mora S, Ames JM, Manson JE. Low-dose aspirin in the primary prevention of cardiovascular disease: Shared decision making in clinical practice. JAMA 2016; 316: 709-10.
10. Salathé M, Bengtsson L, Bodnar TJ, et al. Digital epidemiology. PLoS Comput Biol 2012; 8(7): e1002616.
11. Kuehn BM. Is there an app to solve app overload? JAMA 2015; 313: 1405-7.
12. Plante TB, Urrea B, MacFarlane ZT, et al. Validation of the Instant Blood Pressure smartphone app. JAMA Intern Med 2016; 176: 700-2.
13. Food and Drug Administration. National Evaluation System for Health Technology (NEST). (http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHReports/ucm301912.htm).
14. Shuren J, Califf RM. Need for a national evaluation system for health technology. JAMA 2016; 316: 1153-4.
15. National Institutes of Health Health Care Systems Research Collaboratory. About us (https://www.nihcollaboratory.org/about-us/Pages/default.aspx).
16. National Institutes of Health Health Care Systems Research Collaboratory. Electronic health records (https://www.nihcollaboratory.org/cores/Pages/ehr.aspx).
17. Richesson R, Smerek M. Electronic health records-based phenotyping. In: Rethinking clinical trials: a living textbook of pragmatic clinical trials. June 27, 2014 (https://sites.duke.edu/rethinkingclinicaltrials/ehr-phenotyping/).
18. National Institutes of Health Health Care Systems Research Collaboratory. Phenotypes, data standards, and data quality (https://www.nihcollaboratory.org/cores/Pages/phenotypes.aspx).
19. Peto R, Collins R, Gray R. Large-scale randomized evidence: large, simple trials and overviews of trials. J Clin Epidemiol 1995; 48: 23-40.
20. ClinicalTrials.gov. What is a clinical study? (https://clinical trials.gov/ct2/about-studies/learn#WhatIs).
21. Meldrum M. "A calculated risk": the Salk polio vaccine field trials of 1954. BMJ 1998; 317: 1233-6.
22. National Patient-Centered Clinical Research Network. ADAPTABLE, the aspirin study - a patient-centered trial (http://www.pcornet.org/aspirin/).
23. Califf RM, Sugarman J. Exploring the ethical and regulatory issues in pragmatic clinical trials. Clin Trials 2015; 12: 436-41.
24. National Institutes of Health Health Care Systems Research Collaboratory. Demonstration projects (https://www.nihcollaboratory.org/demonstration-projects/Pages/default.aspx).
25. Anderson ML, Califf RM, Sugarman J. Ethical and regulatory issues of pragmatic cluster randomized trials in contemporary health systems. Clin Trials 2015; 12: 276-86.
26. Gradman AH, Vekeman F, Eldar-Lissai A, Trahey A, Ong SH, Duh MS. Is addition of vasodilators to loop diuretics of value in the care of hospitalized acute heart failure patients? Real-world evidence from a retrospective analysis of a large United States hospital database. J Card Fail 2014; 20: 853-63.
27. Tavris DR, Dey S, Albrecht-Gallauresi B, et al. Risk of local adverse events following cardiac catheterization by hemostasis device use - phase II. J Invasive Cardiol 2005; 17: 644-50.
28. Food and Drug Administration. Pradaxa (dabigatran etexilate mesylate): drug safety communication - safety review of postmarket reports of serious bleeding events (http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedical Products/ucm282820.htm).
29. Ioannidis JP, Tarone R, McLaughlin JK. The false-positive to false-negative ratio in epidemiologic studies. Epidemiology 2011; 22: 450-6.
30. Califf RM. Pragmatic clinical trials: Emerging challenges and new roles for statisticians. Clin Trials 2016; 13: 471-7.
31. Pearl J. Causality: models, reasoning, and inference. 2nd ed. New York: Cambridge University Press, 2009: 350.
32. Food and Drug Administration. Summary of safety and effectiveness data: HeartWare ventricular assist device. Section X. Summary of primary clinical study (http://www.accessdata.fda.gov/cdrh-docs/pdf10/P100047b.pdf).
33. Food and Drug Administration. FDA news release: FDA approval expands access to artificial heart valve for inoperable patients. September 23, 2013 (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm369510.htm).
34. Food and Drug Administration. PDUFA reauthorization performance goals and procedures fiscal years 2018 through 2022 (http://www.fda.gov/downloads/ForIndustry/UserFees/Prescription DrugUserFee/UCM511438.pdf).
35. Food and Drug Administration. FDA - industry MDUFA IV reauthorization meeting. August 15, 2016 (http://www.fda.gov/downloads/ForIndustry/UserFees/MedicalDeviceUserFee/UCM518203.pdf).